Related MeSH Hierarchy (4)
Diseases [C] » Cardiovascular Diseases [C14] » Heart Diseases » Myocardial Ischemia » Myocardial Infarction » ST Elevation Myocardial Infarction
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Myocardial Ischemia » Myocardial Infarction » ST Elevation Myocardial Infarction
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Ischemia » Infarction » Myocardial Infarction » ST Elevation Myocardial Infarction
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Necrosis » Infarction » Myocardial Infarction » ST Elevation Myocardial Infarction
Description
A clinical syndrome defined by MYOCARDIAL ISCHEMIA symptoms; persistent elevation in the ST segments of the ELECTROCARDIOGRAM; and release of BIOMARKERS of myocardial NECROSIS (e.g., elevated TROPONIN levels). ST segment elevation in the ECG is often used in determining the treatment protocol (see also NON-ST ELEVATION MYOCARDIAL INFARCTION). MeSH
Hierarchy View
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (36)
Phase 3 Indicated Drugs (13)
Phase 2 Indicated Drugs (21)
Other Experimental Indicated Drugs (8)
Organization Involved with Phase 4 Indications (78)
Aristotle University of Thessaloniki
China Resources Zizhu Pharmaceutical Co., Ltd.
Chinese Academy of Medical Sciences
CHINESE ARMED POLICE FORCE GENRAL HOSPITAL
General Hospital of Chinese Armed Police Forces
Guangzhou Recomgen Biotech Co., Ltd.
Huazhong University of Science and Technology
Isala Clinics, Zwolle, The Netherlands
Istituto Clinico Humanitas - Rozzano (MI), Italy
Istituto Clinico Sant'Ambrogio
National University of Singapore
Nicolaus Copernicus University
People's Liberation Army of China
Shanghai Xuhui District Central Hospital
Organization Involved with Phase 3 Indications (60)
Basildon and Thurrock University Hospitals NHS Foundation Trust
Canadian Heart Research Centre
Canadian Institutes of Health Research (CIHR)
Chinese People's Armed Police Forces
Clinical Hospital #15 Clinical Hospital #15 named after O.M.Filatov, Moscow, Russia
Hellenic Cardiovascular Research Society
Hospital e Maternidade Celso Pierro
Investigación Independiente S.A.
Iuliu Hatieganu University of Medicine and Pharmacy
National Health and Medical Research Council, Australia
South Australian Health and Medical Research Institute
Suzhou Landing Pharmaceuticals
Suzhou RxD Biopharmaceutical Co., Ltd
Organization Involved with Phase 2 Indications (59)
Azienda Ospedaliera Ospedale Civile di Legnano
Azienda Ospedaliera San Gerardo di Monza
Azienda Ospedaliera Sant'Anna e San Sebastiano
Federal University of Rio Grande do Sul
Federal University of Santa Catarina
First People's Hospital of Foshan
Fondazione Poliambulanza Istituto Ospedaliero
Foundation IRCCS San Matteo Hospital
Gottfried Wilhelm Leibniz Universität Hannover
Justus Liebig University Giessen
National Heart, Lung, and Blood Institute (NHLBI)
National Institute on Aging (NIA)
Ospedale Bassini Cinisello Balsamo
Papworth Hospital NHS Foundation Trust
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (35)
Hamilton Health Sciences Corporation
Henan University of Traditional Chinese Medicine
Puyang Oil Field General Hospital
Russian Academy of Medical Sciences
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
